These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 33009630)

  • 1. Correction to: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence.
    Ehlers CL; Benedict J; Wills D; Sanchez-Alavez M
    Psychopharmacology (Berl); 2020 Nov; 237(11):3507. PubMed ID: 33009630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSPH-D-18-00526: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence.
    Ehlers CL; Benedict J; Wills D; Sanchez-Alavez M
    Psychopharmacology (Berl); 2020 Oct; 237(10):2917-2927. PubMed ID: 31659377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats.
    Gamble MC; Katsuki F; McCoy JG; Strecker RE; McKenna JT
    Neuroscience; 2021 May; 463():30-44. PubMed ID: 33737028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.
    Coborn JE; DePorter DP; Mavanji V; Sinton CM; Kotz CM; Billington CJ; Teske JA
    Int J Obes (Lond); 2017 Aug; 41(8):1256-1262. PubMed ID: 28392556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
    Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
    ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.
    Winrow CJ; Tanis KQ; Reiss DR; Rigby AM; Uslaner JM; Uebele VN; Doran SM; Fox SV; Garson SL; Gotter AL; Levine DM; Roecker AJ; Coleman PJ; Koblan KS; Renger JJ
    Neuropharmacology; 2010 Jan; 58(1):185-94. PubMed ID: 19596018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.
    Yao L; Ramirez AD; Roecker AJ; Fox SV; Uslaner JM; Smith SM; Hodgson R; Coleman PJ; Renger JJ; Winrow CJ; Gotter AL
    J Neurochem; 2017 Jul; 142(2):204-214. PubMed ID: 28444767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization.
    Cady RJ; Denson JE; Sullivan LQ; Durham PL
    Neuroscience; 2014 Jun; 269():79-92. PubMed ID: 24685439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain.
    McDonald T; Liang HA; Sanoja R; Gotter AL; Kuduk SD; Coleman PJ; Smith KM; Winrow CJ; Renger JJ
    J Neurogenet; 2016 Mar; 30(1):32-41. PubMed ID: 27276194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.
    Mavanji V; Perez-Leighton CE; Kotz CM; Billington CJ; Parthasarathy S; Sinton CM; Teske JA
    Sleep; 2015 Sep; 38(9):1361-70. PubMed ID: 25845696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for orexinergic mechanisms in migraine.
    Hoffmann J; Supronsinchai W; Akerman S; Andreou AP; Winrow CJ; Renger J; Hargreaves R; Goadsby PJ
    Neurobiol Dis; 2015 Feb; 74():137-43. PubMed ID: 25447225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
    Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
    Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
    ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking of orexin receptors in the paraventricular nucleus of the thalamus has no effect on the expression of conditioned fear in rats.
    Dong X; Li Y; Kirouac GJ
    Front Behav Neurosci; 2015; 9():161. PubMed ID: 26136671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
    Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
    Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.